SCHEMBL1708210

SCHEMBL1708210

COC(=O)c1cccc(Nc2ccc(C)cc2N)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.52
ALDH1A1 P00352 3/20 0.46
CFTR P13569 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SLC6A4 P31645 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 4/20 0.43
CISD2 Q8N5K1 1/20 0.43
PTGER4 P35408 1/20 0.42
MAPK13 O15264 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
MAPK14 Q16539 1/20 0.42
MAPT P10636 3/20 0.42
ALOX15 P16050 1/20 0.42
P2RX7 Q99572 1/20 0.42
POLB P06746 1/20 0.42
ATM Q13315 1/20 0.42
CDC25B P30305 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707815 0.87 ALDH1A1 (0.44) FFAR4ALDH1A1CFTRHSD17B10SLC6A4
SCHEMBL1707810 0.87 LMNA (0.54) FFAR4ALDH1A1CFTRHSD17B10SMN1; SMN2
SCHEMBL1707753 0.86 ALDH1A1 (0.60) FFAR4ALDH1A1CFTRHSD17B10SMN1; SMN2
SCHEMBL1707910 0.84 CFTR (0.60) FFAR4ALDH1A1CFTRHSD17B10SMN1; SMN2
SCHEMBL1708315 0.83 LMNA (0.45) FFAR4ALDH1A1CFTRHSD17B10SMN1; SMN2
SCHEMBL1708579 0.79 ALDH1A1 (0.44) FFAR4ALDH1A1CFTRHSD17B10SLC6A4
SCHEMBL1707847 0.79 LMNA (0.54) FFAR4ALDH1A1CFTRHSD17B10SMN1; SMN2
SCHEMBL1707741 0.79 LMNA (0.50) FFAR4ALDH1A1CFTRHSD17B10SMN1; SMN2
SCHEMBL1707792 0.77 ALDH1A1 (0.51) FFAR4ALDH1A1CFTRHSD17B10SMN1; SMN2
SCHEMBL20442581 0.75 CFTR (0.59) ALDH1A1CFTRHSD17B10SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
EP-2440541-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-04-18 EP disclosed
WO-2010143733-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF GPR119, INSR, GLP1R FFAR4 23/4885ALDH1A1 3930/4885CFTR 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.